-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
On December 5, Betta Pharmaceuticals issued a press release stating that it has received a new drug clinical trial approval notice issued by the US FDA, agreeing to its fourth-generation EGFR inhibitor BPI-361175 tablets for the treatment of EGFR C797S mutations and others Drug clinical trial application for non-small cell lung cancer with EGFR-related mutations
As we all know, the morbidity and mortality of lung cancer remain high regardless of whether it is in the world or in China
According to the press release, BPI-361175 is a new molecular entity compound independently developed by Betta Pharmaceuticals.
Preclinical data shows that BPI-361175 has the same biological activity in vivo and in vitro, can effectively inhibit the proliferation of tumor cells carrying EGFR C797S mutations, and has shown good anti-tumor effects on multiple xenograft tumor models carrying EGFR-related mutations
The press release also pointed out that the current domestic and foreign drugs that carry the EGFR C797S mutation are in the preclinical or early clinical stage, and no drugs are on the market
Reference materials:
[1] Beida Pharmaceuticals' fourth-generation EGFR inhibitor BPI-361175 was approved for clinical use in the U.
[2] Beida Pharmaceuticals' fourth-generation EGFR inhibitor BPI-361175 was approved for clinical trials.
